For CS-resistant or dependent patients with ITP, thrombopoietin receptor agonists (TPO-RAs), rituximab (RTX) and splenectomy have been recommended as second-line treatments in recently published guidelines including the Japanese guidelines [2, 3]. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.